No Data
Growth 250 rebounds, space ventures are STAR = Emerging Markets, 17th.
The TSE Growth Market 250 Index rebounded. Buying focused on major stocks resulted in a steady trend. Space ventures such as Synspective <290A.T>, ispace <9348.T>, and Astroscale Holdings <186A.T> are STAR. Plaid <4165.T> and Heartsseed <219A.T> also saw increases. Trial Holdings <141A.T> and AI Robotics <247A.T> are low. In the standard category.
Advanced Reading Strategy Command Room = Heart Seed: Attention on the promising heart failure treatment progress, also gaining attention at the World Expo.
The biotech company Heartseed <219A.T> is likely to draw attention at the Osaka-Kansai Expo. It has developed "HS-001," which treats heart failure by injecting and transplanting allogeneic iPS cell-derived cardiomyocytes into the affected area through an open-heart surgery, regenerating and strengthening the cells to cure heart failure. Currently, there are 10 cases undergoing clinical trials, with 5 cases at a low dose and 5 cases at a high dose. The next generation product, "HS-005," will implant cardiomyocytes into the affected area via catheter without open-heart surgery, reducing the burden on patients.
Growth 250 plummeted, with declines in SanBio ETC = Emerging Markets, September 9.
The Tokyo Stock Exchange Growth Market 250 Index has sharply declined. Due to concerns over a trade war, there is a tendency for stock prices to drop again, with Emerging Markets also experiencing widespread losses. Major stocks such as Cover <5253.T> and SanBio <4592.T> have fallen. The drops of Genda <9166.T> and iSpace <9348.T> were also noticeable. Qualips <4894.T> and Heartseed <219A.T> have increased. In the Standard sector, Harmonic Drive Systems <6324.T> has reached new lows.
CellSeed - temporarily reached the upper limit, with a rapid rise in Qualisys expanding interest in drug discovery-related stocks.
The stock reached a temporary high. Qualips <4894> announced its application for manufacturing and selling regenerative medicine products derived from iPS cell-derived cardiac muscle cell sheets, which has led to a surge in buying interest, reaching a stop-high buying indication, expanding into drug discovery-related stocks. Besides Cellseed, K Pharma <4896> and Heartseed <219A> are also rapidly rising. Cellseed disclosed the start of clinical trials for allogenic cartilage cell sheets on March 24, which seems to be attracting renewed buying interest.
Premium Stocks News = The theory of Prime Minister Ishiba's resignation is gaining strength, and attention is once again focused on "related to Takai."
The imposition of reciprocal tariffs announced by President Trump is shocking the world. There is a concern that it could significantly impact the Japanese economy, and the pressure on the Ishiba administration seems likely to intensify. Within the ruling Liberal Democratic Party, calls for the Prime Minister's resignation are being openly voiced, and there is potential for political expansion ahead of the House of Councillors elections in July. <Considering the diplomatic crisis and the House of Councillors elections> At a meeting held on the 3rd by the "Conservative Unity Association," composed of conservative members of the Liberal Democratic Party, demands for resignation were raised, stating "The Ishiba administration cannot win the House of Councillors elections."
The Growth 250 fell for four consecutive days, with continued Sell on major stocks in Emerging Markets on the 1st.
The Tokyo Stock Exchange Growth Market 250 Index has fallen for four consecutive days. Selling continues mainly among leading stocks. Companies such as Cover <5253.T>, BASE <4477.T>, and Heartspeed <219A.T> have seen declines. Due to worsening market conditions, there has been selling also on recently IPO'd stocks like Dynamic Map Platform <336A.T> and ZenmuTech <338A.T>. The Standard Market is also showing a weak trend. Provided by Wealth Advisor Co.
